r-HuEPO低反应性患者应用骨化三醇治疗的临床观察(1)
 |
| 第1页 |
参见附件。
[摘要] 目的 探讨应用骨化三醇对血液透析促红细胞生成素(r-HuEPO)低反应性患者的影响。 方法 随机将20例r-HuEPO低反应性患者分成观察组和对照组各10例，观察组给予骨化三醇口服治疗，对照组未给予骨化三醇治疗，两组均常规进行血液透析，并补充铁剂、r-HuEPO、叶酸、维生素B12；观察分析两组患者治疗前后血清甲状旁腺激素(iPTH)、血红蛋白(Hb)、血细胞比容(Hct)、血钙(Ca)、血磷(P)检测结果。结果 观察组治疗后血清iPTH、P下降明显，Ca、Hb、Hct升高明显，差异有统计学意义(P < 0.05)，对照组治疗前后患者iPTH、Hb、Hct、Ca、P水平差异无统计学意义(P > 0.05)；两组患者治疗前血清iPTH、Hb、Hct、Ca、P水平差异无统计学意义(P > 0.05)，治疗后观察组比对照组血清iPTH、P下降明显，Ca、Hb、Hct升高明显，差异有统计学意义(P < 0.05)。 结论 对于维持性血液透析促红细胞生成素低反应性患者给予口服骨化三醇治疗，可以降低患者血清iPTH水平，从而提高患者对r-HuEPO的反应性，对于改善贫血等治疗效果满意。
[关键词] 血液透析；促红细胞生成素；低反应性；贫血；甲状旁腺激素
[中图分类号] R459.5 [文献标识码] A [文章编号] 1674-4721(2012)03(c)-0029-02
Clinical observation of the treatment in r-HuEPO patients with low reaction of the application of calcitriol
GUAN Wenming
Department of Medical Ward Two，the Second People's Hospital of Luohe City in Henan Province, Luohe 462000, China
[Abstract] Objective To explore the application of calcitriol hemodialysis erythropoietin (r-HuEPO) low reaction of the influence of the patients. Methods Twenty cases of random r-HuEPO low reaction of the patients were randomly divided into trial group and control group every 10 cases, the observation group were given calcitriol oral therapy, the control group were not given calcitriol treatment, both groups routine blood dialysis, and complement iron agent, r-HuEPO, folic acid, vitamin B12; Observed and analyzed two groups of patients before and after treatment serum parathyroid hormone (iPTH), the hemoglobin (Hb), red blood cell deposited (Hct), blood calcium (Ca), blood phosphorus (P) test results. Results The observation group before and after treatment iPTH serum, P down significantly, Ca, Hb, Hct were rise obvious, the difference was statistically significant (P < 0.05), and the control group before and after treatment, iPTH Hb, Hct, Ca, P level of difference was statistically significant (P > 0.05); Two groups of patients serum iPTH, Hb before treatment, Hct, Ca, P level of difference was statistically significant (P > 0 ......
您现在查看是摘要介绍页，详见PDF附件(1655kb)。